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Abstract
Genetic defects in pyruvate dehydrogenase complex (PDC) cause lactic acidosis, neurological deficits, and often early
death. Most mutations of PDC are localized in the K subunit of the pyruvate dehydrogenase (E1) component. We have
kinetically characterized a patient’s missense mutation KH44R in E1K by creating and purifying three recombinant human
E1s (KH44R, KH44Q, and KH44A). Substitutions at histidine-15 resulted in decreased Vmax values (6% KH44R; 30%
KH44Q; 90% KH44A) while increasing Km values for thiamine pyrophosphate (TPP) compared to wild-type (KH44R, 3-fold;
KH44Q, 7-fold; KH44A, 10-fold). This suggests that the volume of the residue at site 15 is important for TPP binding and
substitution by a residue with a longer side chain disrupts the active site more than the TPP binding site. The rates of
phosphorylation and dephosphorylation of KH44R E1 by E1-kinase and phospho-E1 phosphatase, respectively, were similar
to that of the wild-type E1 protein. These results provide a biochemical basis for altered E1 function in the KH44R E1
patient. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mammalian pyruvate dehydrogenase complex
(PDC) is composed of multiple copies of several
components, namely, pyruvate dehydrogenase (E1),
dihydrolipoamide acetyltransferase (E2) and dihy-
drolipoamide dehydrogenase (E3), an E3-binding
protein (E3BP), and two regulatory components,
E1-kinase (PDK) and phospho-E1 phosphatase
(PDP) [1^4]. PDC catalyzes the oxidative decarbox-
ylation of pyruvate, using CoASH and NAD, to
acetyl-CoA with the concomitant formation of CO2
and NADH [1,4]. E1, an K2L2 heterotetramer, cata-
lyzes the rate-limiting step in the PDC reaction [5].
E1 activity consists of two partial reactions: (i) the
decarboxylation of pyruvate and (ii) the reductive
acetylation of lipoyl moieties covalently linked to E2.
PDC is controlled post-translationally by phos-
phorylation (inactivation) and dephosphorylation
(reactivation) of the E1 component by several iso-
forms of PDK and PDP, respectively [6^8]. E1 can
be phosphorylated by PDK on three serine residues,
serine 293 (site 1), serine 300 (site 2) and serine 232
(site 3), on each of its K subunits. Phosphorylation of
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any one site on either K subunit is enough for com-
plete inactivation of the E1 component (and hence
PDC) [9,10]. It has been shown previously that the
phosphorylation rates of the serine residues are site-
speci¢c [9,10]; however, the order of dephosphoryla-
tion is random [10,11].
Since PDC controls the oxidation of pyruvate de-
rived from carbohydrates and some amino acids,
PDC de¢ciency limits the oxidation of carbohydrates
in the organism. A majority of patients displaying
PDC de¢ciency have been found to have a de¢ciency
in the E1 component. Of these 130 patients, approx-
imately 70 have been shown to have point mutations
in E1, all in the K subunit [12]. The remaining 60
patients were found to have either insertion or dele-
tion mutations [12]. E1 de¢ciency is an X-linked dis-
order. Mutation in males results in severe lactic
acidosis and varied neurological dysfunctions, while
in females (depending on X-chromosome inactiva-
tion) there is little increase in blood lactate but neu-
rological defects and structural abnormalities are
much more severe [13]. Since glucose is the major
source of energy in the brain, there is a lack of en-
ergy production and thus dysfunction in the brain. A
rationale therapy for these mutations is to limit the
amount of carbohydrate intake and increase the
amount of fat consumed [14,15]. Another strategy
is to give the patient high doses of thiamine [16^
18]. Several patients, reported thus far, have shown
improvement by pharmacological doses of thiamine
[18^20].
One patient, who was thiamine responsive, was
reported to have a histidine to arginine substitution
at residue 15 in the E1K subunit [18]. Addition of
high concentrations of thiamine pyrophosphate
(TPP) to lymphoblastoid and ¢broblast extracts
from this patient resulted in a marked increase in
PDC activity in vitro. The activity of the patient’s
PDC was extremely low at 0.1 WM TPP while at 400
WM TPP, the activity was approximately 35% of
normal controls (Km for TPP of control ¢broblasts
is about 0.07 WM) [18]. An immunoblot analysis us-
ing anti-E1 antibodies showed control levels of the
individual subunits [18]. This suggested that the pa-
tient’s enzyme was catalytically less active. The aim
of this study was to elucidate the involvement of
histidine-15 in E1K on the human E1 catalysis and
regulation.
2. Materials and methods
2.1. Plasmid constructs
The recombinant expression vector pQE-9:E1K/L
was engineered previously in this laboratory [21].
Plasmids were puri¢ed using a Wizard Plus Mini-
Preps DNA Puri¢cation System (Promega). The
primers used for site-directed mutagenesis were syn-
thesized by the CAMBI Nucleic Acid Facility at this
university (Table 1). Site-directed mutagenesis was
done using a two-step polymerase chain reaction
(PCR) protocol for the engineering of the KH44R
and KH44Q mutant E1K inserts [22]. These Bam-
HI-digested inserts were ligated into BamHI-di-
gested, 5P-dephosphorylated pQE-9 vectors to form
the expression vectors pQE-9:H44R E1K and pQE-
9:H44Q E1K. The pQE-9:H44A E1K vector was cre-
ated using a QuickChange Site-directed Mutagenesis
kit (Stratagene). The E1K inserts (V1.1 kb) of the
mutant pQE-9 expression vectors were sequenced uti-
lizing the dideoxy termination method using Seque-
nase. Mutant constructs with the correct sequence
were digested with PvuI and SalI simultaneously
and the resulting 1.85 kb fragment was puri¢ed using
a QiaexII Gel Extraction kit (Qiagen). A 3.8 kb
pQE-3:E1L wild-type fragment digested with XhoI
and PvuI was then ligated to this 1.85 kb fragment.
The resulting ligations formed the vectors pQE-
9:H44R E1K/L, pQE-9:H44Q E1K/L, and pQE-
9:H44A E1K/L. The ligation mixtures were trans-
formed into an Escherichia coli M15 CaCl2 compe-
tent cell line containing pDM1.1, which encodes the
lac repressor. The 5P end, the site of mutation, and
the 3P end of the E1K/L coexpression vectors were
then resequenced as above.
2.2. Overexpression of recombinant proteins
The wild-type and mutant E1 proteins encoded by
these plasmids were overexpressed and puri¢ed by a
slight modi¢cation of the procedure described previ-
ously [21]. The modi¢cations included the addition of
5% glycerol to all of the bu¡ers and 50 mM imida-
zole to the wash bu¡er. E1 was concentrated either
by 60% ammonium sulfate precipitation or by using
a Ultrafree-15 Centrifugal Filter Device (50 kDa mo-
lecular mass cuto¡) (Millipore). A coexpression vec-
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tor containing the cDNAs encoding the human E2
component and the E3BP was a gift from Dr. Robert
A. Harris [23]. E2^E3BP subcomplex was overex-
pressed and puri¢ed by the method of Yang et al.
[24,25]. The E2^E3BP subcomplex was s 90% pure
and had no detectable E. coli PDC or K-ketogluta-
rate dehydrogenase complex activities. Recombinant
human E3 protein was overexpressed and puri¢ed
using a vector not yet published (Y. Hong, M.S.
Patel, unpublished construct) by methods reported
previously [26].
BL21(DE3) E. coli cell lines harboring either ex-
pression vectors containing the cDNA for rat PDK1
or PDK2 were generous gifts from Dr. R.A. Harris.
Overexpression and puri¢cation of PDK1 and PDK2
were done as previously published [25,27]. Aliquots
were stored at 380‡C in 50% glycerol. A pET-28a
vector containing the cDNA for rat PDP1 was a
generous gift from Dr. R.A. Harris. This vector
was transformed into CaCl2 competent BL21(DE3)
E. coli cells, containing pGroESL, a vector encoding
the chaperonins GroES and GroEL, a gift from Dr.
Anthony A. Gatenby (DuPont). PDP1 was puri¢ed
as described by Huang et al. [28]. The fractions con-
taining PDP1 were pooled, concentrated and glycerol
was added to a ¢nal concentration of 50%.
Purities of puri¢ed proteins were determined by
densitometry of 12% sodium dodecyl sulfate (SDS)^
polyacrylamide gels after Coomassie blue staining.
Protein concentrations were measured by Bio-Rad
protein assay using bovine serum albumin as stan-
dard.
2.3. Pyruvate dehydrogenase complex activity assay
Overall PDC activity was assayed by PDC recon-
stitution assay by measuring the formation of
NADH [29]. For reconstitution of PDC, 1 or 2 Wg
of E1 with an excess amount of both E2^E3BP (3 or
6 Wg) and E3 (3 or 6 Wg) was incubated in 50 mM
potassium phosphate, pH 7.5. For measurement of
PDC activity, reconstituted PDC was incubated with
2 mM MgCl2, 1.4 mM NAD, 4 mM cysteine, 156
WM CoASH, and TPP concentrations varying from
350 to 7500 WM in a 1-ml reaction volume. The re-
action was started by the addition of pyruvate to a
¢nal concentration of 2 mM and the change in ab-
sorbance at 340 nm was measured. One unit of en-
zyme activity is equivalent to one Wmole NADH
formed per minute. E1 activity was measured by
the reduction of 2, 6-dichlorophenolindophenol
(DCPIP) at 600 nm [25,30]. The conditions for
DCPIP assay were as follows: 50 mM potassium
phosphate bu¡er (pH 7.0), 500 WM TPP, 10 mM
MgCl2, and 100 WM DCPIP with 10^30 Wg E1; the
reaction was started by the addition of pyruvate to
5 mM in a ¢nal volume of 1 ml.
2.4. E1 phosphorylation assay
Incorporation of 32P from [32P]ATP into E1 was
measured as described previously [10]. E1 (10 Wg)
was incubated in 20 mM potassium phosphate bu¡er
(pH 7.0) containing 10 Wg E2^E3BP, 1 mM MgCl2,
0.1 mM EDTA, 2 mM dithiothreitol, 200 WM ATP
(speci¢c radioactivity of 460^960 cpm/pmol ATP)
with V10 ng of PDK1 or PDK2 at 30‡C [10]. At
various time intervals, aliquots were removed and
placed on 10% trichloroacetate (TCA) presoaked ¢l-
ter papers and dropped into a 10% TCA, 10 mM
pyrophosphate solution. These ¢lter papers were
washed, air-dried and the radioactivity associated
was measured by a Beckman LS 6500 Multi-Purpose
scintillation counter.
Site 3 was shown to be phosphorylated only by
PDK1 and not PDK2 [31]. That allowed us to study
phosphorylation of site 3 only. For site-speci¢c 32P-
phosphorylation of site 3, E1 protein was phosphor-
ylated as mentioned above by PDK2 in the presence
of the E2^E3BP subcomplex with 200 WM ATP
(non-radioactive). After sites 1 and 2 were phosphor-
ylated, 10 Wg PDK1 and [32P]ATP (¢nal speci¢c ra-
dioactivity of 1460^1500 cpm/pmol ATP) were added
and incorporation of [32P]PO4 was measured as men-
tioned above.
2.5. E1 dephosphorylation assay
Dephosphorylation of E1 was measured using a
modi¢cation of Korotchkina and Patel [10]. Phos-
phorylation reactions (200 Wl), containing 20 Wg of
wild-type or mutant E1 proteins, 0.06 Wg PDK1 or
PDK2 and 200 WM [Q-32P]ATP (speci¢c radioactivity
of 1460^1500 cpm/pmol), were stopped by the deple-
tion of ATP. This was accomplished by adding 4 Wg
yeast hexokinase and 500 WM glucose to the reaction
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mixture and incubating for 15 min at 30‡C. MgCl2
and CaCl2 were then added to ¢nal concentrations of
10 mM and 100 WM, respectively. Dephosphoryla-
tion was started by the addition of 1.5 Wg PDP1.
At various time intervals, aliquots were removed
and added to SDS-protein sample bu¡er, boiled for
1 min and stored at 320‡C until they were separated
on 10% SDS^polyacrylamide gels. Gels were dried
and the amount of phosphorylated E1 was measured
by densitometry by a BioRad phosphoimager.
2.6. Binding of E1 to the E2^E3BP subcomplex
Binding studies of E1 to the E2^E3BP subcomplex
were carried out in order to determine whether the
mutant E1 proteins were able to bind to the E2^
E3BP subcomplex as well as the wild-type enzyme.
The ¢rst approach consisted of measuring PDC spe-
ci¢c activity by PDC reconstitution assay with in-
creasing amounts of E1 protein (0^2 Wg) and con-
stant amounts of E2^E3BP subcomplex (1 Wg) and
E3 (0.85 Wg). The data were plotted (1/speci¢c activ-
ity versus the ratio of E2^E3BP/E1 (Wg/Wg)) in Sigma
Plot (Jandel Scienti¢c, CA). The x-intercept was tak-
en as the minimum amount of E1 protein needed to
fully activate 1 Wg of E2^E3BP subcomplex.
Using the second experimental approach E1s (100,
150 and 200 Wg) were incubated with E2^E3BP (100
Wg) for 30 min at room temperature in 120 Wl of 50
mM potassium phosphate bu¡er, pH 7.5. One hun-
dred Wl of incubation mixture were subjected to gel-
¢ltration on Superdex 200 HR 10/30 (Amersham
Pharmacia Biotech) to separate E1 bound to E2^
E3BP and unbound E1. Two peaks were detected,
i.e., E1^E2^E3BP and free E1. The integrated areas
of the peaks were calculated by Unicorn 3.21 pro-
gram. The amount of E1 bound to E2 was calculated
by subtracting the integrated area of the peak of E2^
E3BP in the absence of E1 from the integrated area
of the peak of the subcomplex E1^E2^E3BP.
2.7. Thermostability of E1 proteins at 37‡C
The thermostability of the wild-type and the mu-
tant E1 proteins were measured in both the presence
and absence of the E2^E3BP subcomplex. In the
absence of the E2^E3BP subcomplex, E1 protein
(2.1 WM) was incubated at 37‡C in 50 mM potassi-
um phosphate bu¡er (pH 7.0) with TPP concentra-
tion from 0 to 1 mM. In the presence of E2^E3BP
subcomplex, E1 protein (0.8 WM, calculated as tet-
ramer E1) was incubated with 0.05 WM E2^E3BP
(calculated as 60-mer E1) at 37‡C with 0^1 mM
TPP (and 1 mM MgCl2). At various time intervals,
1 or 2 Wg of E1 protein was removed (with E2^
E3BP), reconstituted with a total of 3 or 6 Wg of
E2^E3BP and 3 or 6 Wg of E3, and PDC activity
measured.
3. Results
3.1. Pyruvate dehydrogenase activity
Kinetic analysis showed that the substitution of K-
histidine-44 by arginine, as found in the patient,
caused a 94% reduction in the Vmax, while increasing
the Km value for TPP by only 3-fold (Table 2). Sub-
stitution of this histidine residue by a glutamine res-
idue only caused a 69% reduction in Vmax, but a 7-
fold increase in the Km value for TPP. Substitution
of K-histidine-44 with an alanine residue had no sig-
ni¢cant e¡ect on the mutant enzyme’s Vmax value,
whereas it caused an approximately 10-fold increase
Table 1
Primers used for site-directed mutagenesis
Primer name Mutagenic primers (listed 5P to 3P, nucleotide change is underlined) Nucleotide position
WT GGGCCTTCTTCCAGCCGGTGAAGGTCACATTTCTT 62C27
KH44R GGGCCTTCTTCCAGCCGGCGAAGGTCACATTTC 62C29
KH44Q GGGCCTTCTTCCAGCCGATGAAGGTCACATTTC 62C29
KH44A/ASa GGGCCTTCTTCCAGCCGGGCAAGGTCACATTTCTT 62C29
KH44A/Sa AAGAAATGTGACCTTGCCCGGCTGGAAGAAGGCCC 27C62
aKH44A/AS and KH44A/S are the antisense and sense primers, respectively, used for the construction of the KH44A E1 mutant in-
sert.
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in the Km value for TPP. The mutant proteins had
similar Km values for pyruvate as the wild-type E1
(Table 2). The activities of the E1 mutant proteins in
DCPIP assays were also reduced to the residual ac-
tivity of 17% (KH44R), 43% (KH44Q) and 71%
(KH44A) (Table 2).
3.2. Phosphorylation and dephosphorylation of
KH44R E1
In order to investigate whether the phosphoryla-
tion state of E1 in the patient with the KH44R mu-
tation was contributing to his E1-de¢ciency, the
rates of phosphorylation and dephosphorylation
were measured. The rates of phosphorylation of
wild-type and KH44R E1 sites 1 and 2 by rat
PDK2 were found to be similar for these two pro-
teins (results not shown). Additionally, after phos-
phorylation of sites 1 and 2 by rat PDK2 and ATP,
the rates of phosphorylation of site 3 by rat PDK1
and [32P]ATP were measured for wild-type and
KH44R E1 proteins and found to be similar (results
not shown). The rates of dephosphorylation were
also investigated using recombinant rat PDP1. The
rates of dephosphorylation of sites 1 and 2 for wild-
type and KH44R E1 proteins were measured after
phosphorylation of these E1 proteins by PDK2. The
rates of dephosphorylation of sites 1 and 2 were
similar for wild-type and KH44R E1s. The rate of
dephosphorylation of site 3 only was investigated
using site 3-[32P]phospho-E1 proteins. Again, the
rates of dephosphorylation of wild-type and
KH44R E1 proteins were similar for site 3 (results
not shown). Therefore, the lack of E1 activity in
KH44R E1 patients was not due to an increase in
the ratio of phosphorylated (inactive)/dephosphory-
lated (active) E1.
3.3. Binding of E1 to the E2^E3BP subcomplex
It is postulated that the E1 heterotetramer binds to
the E1-binding domain of the E2 component via its
E1L subunit, as was shown for branched-chain K-
keto acid dehydrogenase [32]. In order to elucidate
whether any of these mutations cause a conforma-
tional change, which is interfering with the interac-
tion of the E1 component with the E2 binding do-
main, the binding of the mutant and wild-type E1s to
the E2^E3BP subcomplex was investigated. Titration
Fig. 1. Reconstitution of wild-type and KH44 mutant E1s with
the E2^E3BP subcomplex. R, Wild-type E1; a, KH44R E1;
O, KH44Q E1; R, KH44A E1. Varying concentrations of E1
were reconstituted with 1 Wg of E2^E3BP subcomplex and 3 Wg
of E3 and PDC activity was measured by PDC reconstitution
assay. Results are means þ S.D..
Table 2
Kinetic parameters of wild-type and mutant E1 proteins using PDC reconstitution and DCPIP assays
Reconstitution assay DCPIP assay
E1 Type Vamax
(units/mg E1)
kcat
(s31)
KmTPPa
(nM)
kcat/Km
(s31 M31U108)
KmPyra
(WM)
kcat/Km
(s31 M31U106)
E1 activitya
(mU/mg E1)
WT 26.5 þ 5.0 68.0 73 þ 13 9.3 50 þ 15 1.4 249 þ 23
KH44R 1.6 þ 0.3 4.1 205 þ 27 0.2 57 þ 17 0.1 42 þ 5
KH44Q 8.2 þ 2.3 21.0 485 þ 8 0.4 59 þ 4 0.4 108 þ 17
KH44A 23.0 þ 3.2 59.0 759 þ 57 0.8 52 þ 17 1.1 176 þ 48
aResults are means þ S.D. of at least four individual determinations.
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of a constant amount of E2^E3BP subcomplex with
a variable amount of E1 protein and subsequent
measurement of PDC activity by reconstitution assay
allowed for the determination of the least amount of
E1 protein needed to saturate the ¢xed amount of
E2^E3BP subcomplex. The ability of the mutant pro-
teins to bind to the E2^E3BP subcomplex varied
little from the wild-type. The E1 proteins showed
saturation ratios of 1.7, 1.2 and 1.2 Wg of E1/Wg of
E2 for wild-type E1, KH44R E1 and KH44Q E1 pro-
teins, respectively (Fig. 1). The theoretical ratio of E1
to E2 (wt/wt) in vivo is approximately 1.3
{[(60UE1K ; Mr 40 183)+(60UE1L ; Mr 35 863)]/
[60UE2; Mr 59 551]}.
The second experimental approach employed was
to study direct binding of E1s with E2^E3BP using
Fig. 3. Stability of KH44R and KH44A E1s at 37‡C in the pres-
ence and absence of the E2^E3BP subcomplex. (A) a, KH44R
E1; R, KH44R E1 with 460 WM TPP; P, KH44R E1 with
1 mM TPP; 8, KH44R E1 in the presence of the E2^E3BP
subcomplex. (B) a, KH44A E1; R, KH44A E1 with 46 WM
TPP; P, KH44A E1 with 240 WM TPP; 8, KH44A E1 in the
presence of the E2^E3BP subcomplex; E, KH44A E1 with 13
WM TPP in the presence of the E2^E3BP subcomplex; b,
KH44A E1 with 65 WM TPP in the presence of the E2^E3BP
subcomplex. Aliquots of E1 (1 Wg) incubated at 37‡C for vary-
ing lengths of time were reconstituted to PDC and activity was
measured in PDC reconstitution assay.
Fig. 2. Binding of wild-type and KH44 mutant E1s to the E2^
E3BP subcomplex. E1 was preincubated with E2^E3BP at the
ratios indicated and subjected to gel-¢ltration on Superdex 200
HP. (A) Bound E1 (the integrated area of the peak E1^E2^
E3BP with subtraction of integrated area of the peak of E2^
E3BP). (B) Unbound E1 (the integrated area of the peak of
E1). Wild-type E1, open bars; KH44A, hatched bars; KH44Q,
black bars; KH44R, crossed bars. Results are means þ S.D. of
3^4 independent experiments.
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gel-¢ltration. Fig. 2 shows the relative amount of the
wild-type and mutant E1s bound to E2^E3BP (A)
and unbound (B) after preincubation of E1s with
E2^E3BP and separation by gel-¢ltration. As can
be seen mutant E1s were bound to E2^E3BP in the
same amounts as the wild-type E1 at three di¡erent
ratios used. The calculated amount of E1 tetramers
bound to the 60-mer of E2 was from 19 (at 100 Wg of
E1/100 Wg of E2^E3BP) to 25 (at 200 Wg of E1/100
Wg of E2^E3BP).
As was expected, these results of both experimen-
tal approaches indicated that none of the mutations
signi¢cantly a¡ect the ability of the mutant E1 pro-
teins to bind to the E2^E3BP subcomplex.
3.4. Thermostability of E1 proteins at 37‡C
The presence of TPP or E2^E3BP subcomplex in
the incubation medium at 37‡C did not have a bene-
¢cial e¡ect on the stability of wild-type E1 over the
time course studied (results not shown). The KH44R
E1 mutant alone was signi¢cantly less stable at 37‡C
than the wild-type E1 in the absence of E2^E3BP
(Fig. 3A). This mutant required a TPP concentration
of 1 mM to stabilize it, similar to wild-type E1. How-
ever, in the presence of E2^E3BP, the stability of
KH44R E1 was similar to the wild-type protein and
it did not require the addition of any TPP (Fig. 3A).
The KH44A E1 protein was signi¢cantly less stable
at 37‡C than the wild-type in the absence of the E2^
E3BP subcomplex (Fig. 3B). The e¡ect of varying
concentration of TPP was investigated and a TPP
concentration of 240 WM was needed in the incuba-
tion solution to stabilize KH44A E1 to wild-type E1
stability. In the presence of the E2^E3BP subcom-
plex, the KH44A E1 mutant required only 65 WM
TPP in the incubation medium to be as stable as
the wild-type E1 protein (Fig. 3B).
KH44Q E1 mutant was much less stable than the
wild-type E1 in the absence of the E2^E3BP subcom-
plex. With a concentration of 460 WM TPP in the
incubation medium, the KH44Q E1 was as stable
as the wild-type protein (Fig. 4A). In the presence
of the E2^E3BP subcomplex, it was still necessary to
have 130 WM TPP to stabilize this protein similar to
the wild-type (Fig. 4B).
4. Discussion
In the past there have been several di¡erent ap-
proaches to elucidate the mechanism of particular
amino acids in the structure^function of mammalian
E1. The most common approaches are chemical
modi¢cation of E1, expression of mutant E1 proteins
in cells lacking endogenous E1, and biochemical
Fig. 4. Stability of KH44Q E1 at 37‡C in the presence and ab-
sence of the E2^E3BP subcomplex. (A) Stability in the absence
of the E2^E3BP subcomplex. E, Wild-type E1; a, KH44Q E1;
R, KH44Q E1 with 130 WM TPP; P, KH44Q E1 with 460 WM
TPP; 8, KH44Q E1 with 520 WM TPP. (B) Stability in the
presence of the E2^E3BP subcomplex. E, Wild-type E1; a,
KH44Q E1; R, KH44Q E1 with 13 WM TPP; P, KH44Q E1
with 65 WM TPP; 8, KH44Q E1 with 130 WM TPP. Aliquots
of E1 (1 Wg) incubated at 37‡C for varying lengths of time were
reconstituted to PDC and activity was measured in PDC recon-
stitution assay.
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analysis of recombinant mutant E1 proteins recreat-
ing the mutations identi¢ed in E1-de¢cient patients.
Chemical modi¢cation entails modifying E1 with
speci¢c chemicals and investigating the a¡ects of
these modi¢cations on E1 activity and its ability to
bind pyruvate and TPP. Chemical modi¢cation of
E1 has identi¢ed several residues in E1 important
for catalysis : a lysine, a histidine, L-arginine-269,
L-tryptophan-165 and K-cysteine-91. Stepp and
Reed provided evidence that a lysine residue in the
E1K subunit is involved in the binding of TPP using
pyridoxal-5P-phosphate and NaCN [33]. Treatment
of pigeon breast muscle E1 with diethylpyrocarbon-
ate, which modi¢es histidine residues, inactivated
PDC catalysis but did not a¡ect TPP or pyruvate
binding [34]. This suggested that a histidine residue
may be important not for the binding of substrates
but for the second partial reaction, as PDC activity
using HETPP as substrate was a¡ected by the mod-
i¢cation [34]. The positions of these two residues,
lysine and histidine, in the primary sequence are still
not known. Using the sulfhydryl speci¢c reagent N-
ethylmaleimide (NEM), cysteine 91 in E1K was
found to be catalytically important [35]. This was
suggested because TPP plus pyruvate protected E1
from inactivation by NEM when preincubated with
the enzyme [35]. N-bromosuccinimide was used to
modify essential tryptophan residue of pigeon E1
and to identify critical tryptophan of bovine E1 as
L-tryptophan-165 [36,37]. Recently a study on the
mutants of K-cysteine-91 and L-tryptophan-165
showed that both residues were involved in TPP
binding and were important for stability of human
E1 [38]. Arginine-269 of E1L subunit was identi¢ed
as a critical amino acid residue protected by TPP
and pyruvate from modi¢cation by pyreneglyoxal
[39].
A second method used to investigate the e¡ects of
mutations in E1 on PDC activity is to express mu-
tant E1 proteins in a E1K null gene cell line. This was
done by Seyda et al. to quantify the e¡ects of muta-
tions of four of the eight histidyl residues in mature
E1K, namely H92, H113, H121, and H292 [40]. Mu-
tation of histidine-92 or histidine-292 in E1K resulted
in the inactivation of E1 [40]. Mutation of histidine-
121 caused a decrease in the level of the K and L
subunits in cell extracts, suggesting that this residue
plays a role in assembly into mature E1 [40]. Histi-
dine-113 mutation had only a marginal e¡ect on E1
activity [40].
Lastly, nature has presented point mutations in
patients that identify critical amino acids in E1. Pa-
tients with these point mutations display the symp-
toms of E1 de¢ciency: severe lactic acidosis, delayed
neurological development, and often times early
death. These mutant E1 proteins can then be recre-
ated by site-directed mutagenesis, overexpressed as
recombinant proteins, and their kinetic parameters
measured. Several mutant E1 proteins found in pa-
tients, namely KM210V, KP217A and KR378H, have
been characterized in this fashion [41]. K-Methionine-
210, which is located in the putative TPP-binding
motif, was found to play a role in TPP binding, while
K-proline-217, also found in the TPP-binding motif,
was found to be critical for structural integrity of the
enzyme [41]. K-Arginine-378, which is found at the
C-terminus, is critical for catalysis [41]. It was by this
method that the biochemical basis for E1-de¢ciency
in an KH44R E1 patient was investigated in the
present study.
Histidine-44 is conserved in eukaryotic E1K se-
quences (e.g., human, rat, pig, yeast, and nematode)
but not in prokaryotic E1K [42^46]. Mutation of his-
tidine-44 to arginine was found in a boy who dis-
played elevated levels of lactate in the blood and
cerebrospinal £uid (CBF) [18]. The patient had nor-
mal levels of E1K and E1L proteins in lymphoblas-
toid cells as measured by Western blotting using anti-
E1 antibodies [18]. Naito et al. showed that increas-
ing dietary thiamine caused a decrease in blood and
CBF lactate levels. The recombinant KH44R E1 pro-
tein (patient’s mutation) was not signi¢cantly di¡er-
ent from the wild-type E1 in any of the following
parameters tested: stability at 37‡C in the presence
of the E2^E3BP subcomplex, ability to bind to the
E2^E3BP subcomplex, its ability to be phosphorylat-
ed at sites 1 and 2 by PDK2 or site 3 by PDK1, and
its ability to be dephosphorylated at all three sites by
PDP1.
E1 catalyzes two partial reactions, which can be
investigated individually by comparing the E1 activ-
ities from DCPIP and PDC reconstitution assays.
Whereas PDC reconstitution assay measures the
rate-limiting step of PDC, reductive acetylation of
lipoyl groups of E2, DCPIP assay measures the de-
carboxylation of pyruvate and the oxidation of acetyl
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moiety to acetate with concomitant reduction of
DCPIP. Since the reduction in activity of KH44R
E1 in DCPIP assay was as severe as in PDC recon-
stitution assay compared to wild-type E1, it suggests
that mutation of K-histidine-44 is most likely inter-
fering with the ¢rst partial E1 reaction, i.e., TPP-de-
pendent decarboxylation of pyruvate.
Interestingly, the H44R, H44Q, and H44A muta-
tions a¡ected Vmax and Km for TPP in an inverse
relationship. Whereas H44R E1 (patient’s mutation)
only increased Km for TPP 3-fold, its Vmax was only
V5% of the wild-type E1. H44Q E1 had a moderate
increase in Km for TPP (7-fold) but was more active
than the H44R E1 (V30% of wild-type). In contrast,
the H44A E1 protein displayed wild-type E1 activity
but had a markedly increase Km for TPP (V10-fold).
As the side chain of the mutated residue at position
44 is reduced in size (e.g., from arginine to glutamine
to alanine), an increase in the Vmax of the mutant
protein is observed and also an increase in the Km
for TPP. This suggests that the size of the side chain
at this location is important for both catalysis and
TPP binding. Since the histidine side chain is not
absolutely necessary for the wild-type level of activity
and glutamine, whose side chain can mimic histi-
dine’s hydrogen bonding, does not rescue the reduc-
tion caused by mutating histidine-44, histidine-44 is
most likely not directly involved in catalysis. It ap-
pears more likely that the size of the side chain has a
certain space limit that once over, causes a local con-
formational change that disturbs the active site of the
protein and thus causes a decrease in catalytic activ-
ity. Substitution of the histidine residue by any of the
three residues studied here caused a marked increase
in the Km value for TPP. This suggests that this res-
idue is playing a role in the binding of TPP either by
the volume, stacking interactions, or by charge inter-
actions of the histidine ring with other residues. A
reported bene¢cial e¡ect of thiamine therapy in this
patient by Naito et al. is supported by a 3-fold
change in the Km value for TPP observed in the
present study [18].
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